Aptose Q1 net loss widens to $13.7M; tuspetinib doublet dosing underway

Aptose Biosciences Inc.

2023-Q1 EPS reported -$0.15

Net loss $13.7M ($0.15/sh) vs $11.5M ($0.12) YoY; R&D spend up to $8.8M.
Cash and investments $35.7M; runway through March 2024.
Tuspetinib APTIVATE trial: dose escalation/exploration complete; doublet with venetoclax dosing initiated with early blast reductions.
Safety review: no drug-induced myelosuppression or DLTs up to 160mg/day in >70 patients.
Anticipated FDA EOP1 meeting in Q2 2023 and clinical data presentation at EHA June 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aptose Biosciences Inc. reported first quarter ended March 31, 2023 results: net income $ (13,676 ), EPS $ (0.15 ).

Period: first quarter ended March 31, 2023
Net income: $ (13,676 )
EPS: $ (0.15 )
Result: reported results

Exact text from the filing

Aptose Biosciences, Inc. Statements of Operations Data (unaudited) ($ in thousands, except per share data) Three months ended March 31, 2023 March 31, 2022 Expenses: Research and development $ 8,811 $ 7,393 General and administrative 5,285 4,107 Operating expenses 14,096 11,500 Other income, net 420 19 Net loss $ (13,676 ) $ (11,481 ) Net Loss per share, Basic and diluted $ (0.15 ) $ (0.12 )

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-003043

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.